Charles B. Klein
Chuck is a first-chair trial lawyer with almost 30 years of experience who litigates significant patent, antitrust, and commercial disputes. He is the litigation office head in Washington, D.C. and was a longtime member of the firm’s Executive Committee, co-chaired the firm’s Intellectual Property Practice, and chaired the firm’s Commercial Litigation Practice. IAM, which ranks him in the Gold tier, described him as a “talisman for major pharmaceutical and biotechnology businesses” who is “no stranger to billion-dollar cases.” Managing Intellectual Property likewise recognized him as an “IP Star.” Six of Chuck’s first-chair victories (including three trial wins) have been mentioned in the “Litigator of the Week” column published by The American Lawyer.
Key Matters
Serving as lead trial and appellate counsel, Chuck obtained a trial judgment, affirmed on appeal, of noninfringement related to a stress-test agent. Serving as lead trial and appellate counsel, he obtained a trial judgment, affirmed on appeal, invalidating six patents related to a drug used to treat very high triglyceride levels. Serving as lead trial and appellate counsel, he obtained a trial judgment, affirmed on appeal, invalidating four patents related to a multiple sclerosis drug. Also serving as lead trial and appellate counsel, he convinced the Federal and D.C. Circuits to deny requests for injunctive relief related to a drug that treats gout. Serving as lead trial counsel, he obtained a trial judgment of non-infringement and invalidity regarding an insomnia drug. He obtained the first injunction under the Hatch-Waxman counterclaim provision—a significant ruling for the generic-drug industry that the Supreme Court ultimately upheld in a 9-0 decision. He also obtained a defense jury verdict in a US$1.7B pharmaceutical antitrust case identified by The Daily Journal as one of the “Top Verdicts of 2011.”
A biotechnology and pharmaceutical ace who continues to achieve excellent results...
IAM Patent 1000